Back to Search
Start Over
Assessing delayed penicillin hypersensitivity using the PENFAST+ score.
- Source :
-
Frontiers in allergy [Front Allergy] 2023 Nov 13; Vol. 4, pp. 1302567. Date of Electronic Publication: 2023 Nov 13 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Introduction: Approximately 10% of individuals report a suspected allergy to penicillin, but according to allergy work-ups, only 10%-15% of them are truly allergic. A clinical decision score, the PEN-FAST, was developed and validated to identify adults with low-risk penicillin allergy.<br />Objectives: The objective of this study was to improve the performance of the PEN-FAST score, particularly for those with delayed hypersensitivity (HS), by improving the negative predictive value.<br />Methods: STEP 1: Retrospective evaluation of the PEN-FAST score in patients with proven immediate and delayed penicillin allergy. STEP 2: Identification of additional criteria among Step 1 patients misclassified by PEN-FAST score. Development of the PEN-FAST+ score using multivariable logistic regression in a prospective cohort of patients with a suspicion of HS to penicillin. STEP 3: Comparison of diagnostic performances of PEN-FAST and PEN-FAST+ scores.<br />Results: The PEN-FAST score showed limitations in predicting the relapse of immediate skin HS or delayed maculopapular exanthema, with 28.6% and 38.4% of patients misclassified, respectively. We identified two potential additional criteria: skin rash lasting more than 7 days and immediate reaction occurring in less than 1 h (generalized or localized on palmoplantar area or scalp itching/heat feeling). A total of 32/252 (12.7%) patients were confirmed to be allergic to penicillin. With PEN-FAST, 37% of patients ( n = 10) with delayed allergic penicillin HS were misclassified. With PEN-FAST+, 3 patients with delayed HS confirmed by a ST (11.1%) were misclassified. The AUC was significantly higher for PEN-FAST+ than PEN-FAST (85% vs. 72%, p = 0.03).<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (© 2023 Castagna, Chasset, Autegarden, Le Thai, Amsler, Barbaud and Soria.)
Details
- Language :
- English
- ISSN :
- 2673-6101
- Volume :
- 4
- Database :
- MEDLINE
- Journal :
- Frontiers in allergy
- Publication Type :
- Academic Journal
- Accession number :
- 38026134
- Full Text :
- https://doi.org/10.3389/falgy.2023.1302567